Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax.

Authors

Amer M Zeidan, Ruizhi Zhao, Arthur Voegel, Dina Christensen, Maryia Zhdanava, Anabelle Tardif-Samson, Claire Vanden Eynde, Harold Keer, Dominic Pilon, Fang Sun

Published in

Leukemia & lymphoma. Pages 1-10. Oct 28, 2026. Epub Oct 28, 2026.

Abstract

Parenteral hypomethylating agents (HMAs) combined with venetoclax are a first-line treatment for newly diagnosed acute myeloid leukemia (AML) considered ineligible for intensive chemotherapy. Using a retrospective claims database (Humana Healthcare Research Database; 01/01/2019-12/31/2024), time burden, time at home, treatment patterns and persistence were characterized among adults with newly diagnosed AML treated with HMA + venetoclax, from index (first parenteral HMA claim) through end of follow-up (earliest of death, end of insurance eligibility, or end of data). Patients (n = 737; median follow-up: 8.0 months) spent a mean of 11.9 days per month on healthcare visits, with 65.0% of time spent at home or not receiving cancer care. Median time to discontinuation or death on HMA therapy when considering any HMA cycle and label-conforming cycles (≥16 days of venetoclax supply; ≥4/3 days of azacitidine/decitabine) was 5.2 and 2.8 months, respectively. These findings highlight the substantial time burden associated with HMA combined with venetoclax.

PMID:
42952121
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.